A groundbreaking study has unveiled a novel treatment that significantly lowers levels of low-density lipoprotein cholesterol (LDL-C), commonly referred to as "bad" cholesterol, by nearly 50%, all without the use of statins. The research team concentrated on PCSK9, a protein that plays a pivotal role in cholesterol regulation. They developed a method to inhibit the production of this protein through specialized DNA-based molecules known as polypurine hairpins (PPRH).
By suppressing PCSK9, this innovative treatment enhances the ability of cells to absorb cholesterol, thereby decreasing its presence in the bloodstream and reducing arterial buildup. Notably, this method aims to eliminate the side effects frequently associated with traditional statin medications.
The findings were published in the journal Biochemical Pharmacology, with contributions from Carles J. Ciudad and Verònica Noé of the University of Barcelona's Faculty of Pharmacy and Food Sciences and the Institute of Nanoscience and Nanotechnology (IN2UB), alongside Nathalie Pamir from the University of Oregon. The research received funding from the Spanish Ministry of Science, Innovation and Universities (MICINN) and the National Institutes of Health (NIH) in the United States.
Mechanism of Action: How PPRHs Target Cholesterol Regulation
PCSK9 has emerged as a crucial target for therapies aimed at lowering cholesterol and reducing cardiovascular risk. This protein binds to LDL receptors on cells, inhibiting their capacity to clear cholesterol from the bloodstream. Elevated PCSK9 levels result in fewer available receptors, leading to increased LDL cholesterol accumulation.
Polypurine hairpins (PPRHs) provide a genetic-level intervention by binding specifically to targeted DNA or RNA sequences, effectively blocking gene activity. In this case, PPRHs inhibit the transcription of the PCSK9 gene, resulting in an increase in LDL receptor levels and enhancing the body's cholesterol clearance. Consequently, overall cholesterol levels decrease, which in turn diminishes the risk of plaque formation.
This study is the first to detail how two specific PPRHs, designated as HpE9 and HpE12, effectively reduce both PCSK9 RNA and protein levels while increasing LDL receptor concentrations.
Professor Carles J. Ciudad explains, "One arm of each chain of the HpE9 and HpE12 polypurines specifically binds to polypyrimidine sequences of exons 9 and 12 of PCSK9, blocking gene transcription and disrupting RNA polymerase activity."
Promising Results from Laboratory Tests
The team conducted tests on liver cells in vitro and on transgenic mice that carry the human PCSK9 gene, yielding promising results. According to Professor Verònica Noé, "HpE12 reduced PCSK9 RNA levels by 74% and protein levels by 87% in liver cells. In transgenic mice, a single injection of HpE12 resulted in a 50% decrease in plasma PCSK9 levels and a 47% reduction in cholesterol levels by day three."
A New Hope in Cholesterol Management
With PCSK9 as a primary target for cholesterol-lowering therapies, various methods have been developed to mitigate its effects, including gene-silencing technologies and existing treatments like Inclisiran. However, PPRHs may present unique advantages due to their cost-effectiveness, stability, and minimal immunogenicity. This PPRH-based approach is expected to avoid the side effects linked to statin therapies.
If validated by further research, this novel strategy could revolutionize cholesterol management, offering a safer, more precise alternative to traditional treatments and significantly reducing the risk of heart disease.